Skip to content
Agentic OS
Menu

Intelligence / B2B SaaS / Acquisitions / Acura Pharmaceuticals, INC

M&Acompleted an acquisition (SEC 8-K)3 Nov 2026

Acura Pharmaceuticals, INC

3 Nov 2026: Completed an acquisition (SEC 8-K) · Pharma and biotech. Recorded in the SEC EDGAR full-text search.

View the source record

Filed
3 Nov 2026
Role
Completed an acquisition
Sector
Pharma and biotech
Sic
2834
Items
1.01, 2.01, 2.03, 9.01
Summary
Acura Forward-Looking Statements Statements in this Current Report constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and these forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as ame
Location
Palatine, IL
State
Illinois
Country
United States
SEC CIK
786947
Reference
0001104659-26-121685
What this signal means

Integration means consolidating tools and vendors: the buyer re-platforms the target, and an acquired company's stack is reviewed by its new owner.

  1. Completed an acquisition leads with 189 of 292, then Sold assets or a business (82).
  2. 103 added in the 30 days to 19 Nov 2026.
Reach them with AOS

Find the decision makers at Acura Pharmaceuticals, INC

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this m&a signal, for your approval.

Start free

Across AOS Research

Other records for Acura Pharmaceuticals, INC in our registers.

More in Completed an acquisition

Acquisitions

See all

Source: SEC EDGAR full-text search, data to 19 Nov 2026. Every Form 8-K reporting Item 2.01 (completion of an acquisition or disposition of assets) filed with the SEC in the last 90 days. The role (buyer, company acquired, seller) is read from the filing's own wording, which is quoted on each row. AOS shows what the public record says; it does not verify or endorse the company.